OVERVIEW

Targa’s proprietary technology addresses the universal setbacks of cell therapy / regenerative medicine and organ transplantation with

• an ancillary product supporting the ever-growing global pipelines of cell therapies
• a pharmacological product protecting and rescuing marginal quality tissues directed towards the ex vivo perfusion market on course to revolutionize global transplant programs